Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the challenges associated with treating adolescent and young adult (AYA) patients with sarcoma.

Videos

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the challenges associated with treating adolescent and young adult (AYA) patients with sarcoma. 

Dr. Federman on Challenges With Treating AYA Patients With Sarcoma

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the use of nanotechnology as a treatment for patients with sarcomas.

Nanotechnology is being examined at UCLA in pediatric patients with bone and soft tissue sarcomas, Federman explains. Nanotechnology is comprised of very small molecules to carry cytoxic agents. Additionally, the molecules can be coated to target cancer cells.

This could offer the ability to spare select organs in the body while delivering higher doses of therapy directly to cancer cells. Thus far, this has been in only tested in preclinical models, Federman adds.

Dr. Federman on Use of Nanotechnology in Sarcomas

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma.

Current research at UCLA’s Jonnson Comprehensive Cancer Center is focused on patients with rare bone and soft tissue sarcoma, which generally occur in children, adolescents, and young adults, Federman says. One ongoing clinical trial is looking at imaging with PET/CT scans to more accurately diagnose and stage these diseases, as well as observe responses to therapies.

A second trial is examining the efficacy of novel targeted chemotherapy agents toward ewing sarcoma and rhabdomyosarcoma. It is hopeful that these agents will improve patient outcomes, Federman says.

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma. 


Noah Federman, MD

Articles

Dr. Federman on Challenges With Treating AYA Patients With Sarcoma

Dr. Federman on Use of Nanotechnology in Sarcomas

Dr. Federman on Ongoing Research in Rare Bone and Soft Tissue Sarcoma